Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Vis graf over relationer

Primære forskningsområder

The overall aim of my study is to identify an intervention that reduces oxidative stress measured by 8-oxoGuo in patients with type 2 diabetes. Due to [Oelze, M. et al., PLoS ONE, 2014] among others we hypothesize empagliflozin has this ability. We conduct a double-blinded, placebo controlled trial, where 34 participants are randomized to either two weeks 25 mg empagliflozin or placebo treatment. Hereby, we are evaluating the effect of empagliflozin on oxidative stress measured by urinary excretion of 8-oxoGuo and 8-oxodG as a measurement of RNA and DNA oxidation, respectively.

ID: 55696267